JP2008518608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518608A5 JP2008518608A5 JP2007539463A JP2007539463A JP2008518608A5 JP 2008518608 A5 JP2008518608 A5 JP 2008518608A5 JP 2007539463 A JP2007539463 A JP 2007539463A JP 2007539463 A JP2007539463 A JP 2007539463A JP 2008518608 A5 JP2008518608 A5 JP 2008518608A5
- Authority
- JP
- Japan
- Prior art keywords
- lna oligonucleotide
- lna
- composition
- conjugate
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 4
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000000260 Warts Diseases 0.000 claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000010153 skin papilloma Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62656304P | 2004-11-09 | 2004-11-09 | |
| US60/626,563 | 2004-11-09 | ||
| US64718605P | 2005-01-25 | 2005-01-25 | |
| US60/647,186 | 2005-01-25 | ||
| US69972105P | 2005-07-15 | 2005-07-15 | |
| US60/699,721 | 2005-07-15 | ||
| US72462105P | 2005-10-07 | 2005-10-07 | |
| US60/724,621 | 2005-10-07 | ||
| PCT/DK2005/000721 WO2006050734A2 (en) | 2004-11-09 | 2005-11-09 | Potent lna oligonucleotides for the inhibition of hif-1a expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011177731A Division JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008518608A JP2008518608A (ja) | 2008-06-05 |
| JP2008518608A5 true JP2008518608A5 (enExample) | 2008-11-27 |
| JP4825807B2 JP4825807B2 (ja) | 2011-11-30 |
Family
ID=36177326
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539463A Expired - Fee Related JP4825807B2 (ja) | 2004-11-09 | 2005-11-09 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2011177731A Withdrawn JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2014031436A Withdrawn JP2014098027A (ja) | 2004-11-09 | 2014-02-21 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011177731A Withdrawn JP2011229540A (ja) | 2004-11-09 | 2011-08-15 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
| JP2014031436A Withdrawn JP2014098027A (ja) | 2004-11-09 | 2014-02-21 | ＨＩＦ−１ａ発現阻害のための強力なＬＮＡオリゴヌクレオチド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7589190B2 (enExample) |
| EP (1) | EP1833840B9 (enExample) |
| JP (3) | JP4825807B2 (enExample) |
| KR (1) | KR101176245B1 (enExample) |
| AT (1) | ATE476441T1 (enExample) |
| AU (1) | AU2005304112B2 (enExample) |
| BR (1) | BRPI0515726A8 (enExample) |
| CA (1) | CA2587173C (enExample) |
| DE (1) | DE602005022768D1 (enExample) |
| DK (1) | DK1833840T3 (enExample) |
| EA (1) | EA014097B1 (enExample) |
| IL (1) | IL183054A0 (enExample) |
| MX (1) | MX2007005558A (enExample) |
| NO (1) | NO341878B1 (enExample) |
| NZ (1) | NZ555644A (enExample) |
| WO (1) | WO2006050734A2 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2752488B1 (en) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| EP2141234B1 (en) | 2003-03-21 | 2016-04-27 | Roche Innovation Center Copenhagen A/S | Short Interfering RNA (siRNA) Analogues |
| US20080249039A1 (en) * | 2004-01-30 | 2008-10-09 | Santaris Pharma A/S | Modified Short Interfering Rna (Modified Sirna) |
| US9447138B2 (en) | 2004-11-09 | 2016-09-20 | Roche Innovation Center Copenhagen A/S | Potent LNA oligonucleotides for the inhibition of HIF-1a expression |
| CA2587173C (en) * | 2004-11-09 | 2016-09-06 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a expression |
| CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
| EP1984382B1 (en) * | 2006-01-27 | 2012-08-15 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
| EP2002004B1 (en) | 2006-03-23 | 2015-10-14 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering rna |
| CA3044969A1 (en) | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
| AU2007296055A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| EP2149605B1 (en) | 2007-03-22 | 2013-07-03 | Santaris Pharma A/S | Short RNA antagonist compounds for the modulation of target mRNA |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| ES2462416T3 (es) | 2007-08-06 | 2014-05-22 | Senju Pharmaceutical Co., Ltd. | Producto farmacéutico que contiene un inhibidor de la expresión de HIF-1 alfa y HIF-2 alfa |
| EP2548962B1 (en) | 2007-09-19 | 2016-01-13 | Applied Biosystems, LLC | Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof |
| JP2010539961A (ja) * | 2007-10-04 | 2010-12-24 | サンタリス ファーマ アー／エス | ＨＩＦ１αの調節のための短いＲＮＡアンタゴニスト化合物 |
| CA2739464C (en) | 2008-10-03 | 2020-03-31 | Curna, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| KR101829469B1 (ko) | 2008-12-04 | 2018-03-30 | 큐알엔에이, 인크. | Ｅｐｏ에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(ｅｐｏ) 관련된 질환의 치료 |
| RU2569182C2 (ru) | 2008-12-04 | 2015-11-20 | КьюРНА,Инк.,US | Лечение заболеваний, связанных с фактором роста эндотелия сосудов (vegf), посредством ингибирования природного антисмыслового транскрипта к vegf |
| KR101866152B1 (ko) | 2008-12-04 | 2018-06-08 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
| KR101682735B1 (ko) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | 뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료 |
| MX2011009751A (es) | 2009-03-16 | 2011-09-29 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2. |
| JP5904935B2 (ja) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療 |
| JP6250930B2 (ja) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療 |
| CN102459596B (zh) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病 |
| CA2761248C (en) | 2009-05-08 | 2023-03-14 | Joseph Collard | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
| JP5922017B2 (ja) | 2009-05-18 | 2016-05-24 | クルナ・インコーポレーテッド | リプログラミング因子に対する天然アンチセンス転写物の抑制によるリプログラミング因子関連疾患の治療 |
| EP2432882B1 (en) | 2009-05-22 | 2019-12-25 | CuRNA, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
| WO2010138806A2 (en) | 2009-05-28 | 2010-12-02 | Curna, Inc. | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| JP5944311B2 (ja) | 2009-06-16 | 2016-07-05 | クルナ・インコーポレーテッド | コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療 |
| JP6128846B2 (ja) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療 |
| EP2446036B1 (en) | 2009-06-24 | 2017-03-01 | CuRNA, Inc. | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
| US8921330B2 (en) | 2009-06-26 | 2014-12-30 | Curna, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
| WO2011011700A2 (en) | 2009-07-24 | 2011-01-27 | Curna, Inc. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
| ES2585360T3 (es) | 2009-08-05 | 2016-10-05 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS) |
| JP6189594B2 (ja) | 2009-08-11 | 2017-08-30 | クルナ・インコーポレーテッド | アディポネクチン（ａｄｉｐｏｑ）に対する天然アンチセンス転写物の抑制によるアディポネクチン（ａｄｉｐｏｑ）関連疾患の治療 |
| CN102482670B (zh) | 2009-08-21 | 2018-06-15 | 库尔纳公司 | 通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病 |
| KR101892760B1 (ko) | 2009-08-25 | 2018-08-28 | 큐알엔에이, 인크. | ＩＱＧＡＰ에 대한 천연 안티센스 전사체의 억제에 의한 ＧＴＰａｓｅ 활성화 단백질을 함유하는 ＩＱ 모티프(ＩＱＧＡＰ)와 관련된 질환의 치료 |
| ES2664591T3 (es) | 2009-09-25 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG |
| AR078770A1 (es) | 2009-10-27 | 2011-11-30 | Elara Pharmaceuticals Gmbh | Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas. |
| CN102712927B (zh) | 2009-12-16 | 2017-12-01 | 库尔纳公司 | 通过抑制膜结合转录因子肽酶，位点1(mbtps1)的天然反义转录物来治疗mbtps1相关疾病 |
| KR101891352B1 (ko) | 2009-12-23 | 2018-08-24 | 큐알엔에이, 인크. | 간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료 |
| JP6031356B2 (ja) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー，インコーポレイテッド | Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療 |
| CA2785177C (en) | 2009-12-29 | 2019-09-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
| KR101838305B1 (ko) | 2009-12-29 | 2018-03-13 | 큐알엔에이, 인크. | ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료 |
| CN102791862B (zh) | 2009-12-31 | 2017-04-05 | 库尔纳公司 | 通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病 |
| JP5886757B2 (ja) | 2010-01-04 | 2016-03-16 | カッパーアールエヌエー，インコーポレイテッド | インターフェロン調節因子８（ｉｒｆ８）に対する天然アンチセンス転写物の阻害によるインターフェロン調節因子８（ｉｒｆ８）関連疾患の治療 |
| EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
| JP6027893B2 (ja) | 2010-01-11 | 2016-11-16 | カッパーアールエヌエー，インコーポレイテッド | 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療 |
| EP2529015B1 (en) | 2010-01-25 | 2017-11-15 | CuRNA, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
| KR101838308B1 (ko) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | 피롤린-5-카르복실레이트 환원효소 1(ｐｙｃｒ1)에 대한 천연 안티센스 전사체의 억제에 의한 ｐｙｃｒ1과 관련된 질환의 치료 |
| CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
| TWI644675B (zh) | 2010-04-09 | 2018-12-21 | 可娜公司 | 藉由抑制纖維母細胞生長因子２１（ｆｇｆ２１）之天然反義轉錄物以治療ｆｇｆ２１相關疾病 |
| RU2693462C2 (ru) | 2010-05-03 | 2019-07-03 | Курна, Инк. | Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt) |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| EP2576783B1 (en) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
| EP2576784B1 (en) | 2010-05-26 | 2017-11-15 | CuRNA, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
| AU2011261213B2 (en) * | 2010-06-04 | 2015-05-21 | Board Of Regents, The University Of Texas System | Regulation of metabolism by miR-378 |
| KR102008708B1 (ko) | 2010-06-23 | 2019-08-08 | 큐알엔에이, 인크. | 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료 |
| CA2805318A1 (en) | 2010-07-14 | 2012-01-19 | Curna, Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
| ES2640755T3 (es) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la Sialidasa 4 (neu4) mediante inhibición del transcrito antisentido natural al gen neu4 |
| US9222088B2 (en) | 2010-10-22 | 2015-12-29 | Curna, Inc. | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| EP2643463B1 (en) | 2010-11-23 | 2017-09-27 | CuRNA, Inc. | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| WO2012082765A2 (en) | 2010-12-16 | 2012-06-21 | The United State Of America. As Represented By The Secretary Department Of Health And Human Services | Methods for decreasing body weight and treating diabetes |
| EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| JP6188686B2 (ja) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー，インコーポレイテッド | フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療 |
| BR112014005234A2 (pt) | 2011-09-06 | 2017-04-11 | Curna Inc | tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas |
| HUE040179T2 (hu) | 2012-03-15 | 2019-02-28 | Curna Inc | Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén |
| JP6452614B2 (ja) | 2012-11-15 | 2019-01-16 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチドコンジュゲート |
| MY197877A (en) * | 2013-06-04 | 2023-07-22 | Harvard College | Rna-guided transcriptional regulation |
| US11479818B2 (en) | 2016-06-17 | 2022-10-25 | Hoffmann-La Roche Inc. | In vitro nephrotoxicity screening assay |
| WO2017216340A1 (en) * | 2016-06-17 | 2017-12-21 | F. Hoffmann-La Roche Ag | In vitro nephrotoxicity screening assay |
| WO2018160772A1 (en) | 2017-02-28 | 2018-09-07 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5278324A (en) | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
| US5250683A (en) | 1991-09-23 | 1993-10-05 | Florida State University | Certain substituted taxanes and pharmaceutical compositions containing them |
| US5227400A (en) | 1991-09-23 | 1993-07-13 | Florida State University | Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them |
| US5272171A (en) | 1992-02-13 | 1993-12-21 | Bristol-Myers Squibb Company | Phosphonooxy and carbonate derivatives of taxol |
| FR2688518B1 (fr) | 1992-03-13 | 1994-05-06 | Rhone Poulenc Rorer Sa | Procede de preparation de derives du taxane. |
| US5248796A (en) | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
| US5254580A (en) | 1993-01-19 | 1993-10-19 | Bristol-Myers Squibb Company | 7,8-cyclopropataxanes |
| US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5882914A (en) | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| AU3455599A (en) | 1998-03-27 | 1999-10-18 | Board Of Trustees Of The Leland Stanford Junior University | Hypoxia-inducible human genes, proteins, and uses thereof |
| US6821724B1 (en) | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
| HK1048639A1 (zh) | 1999-03-18 | 2003-04-11 | 埃克西库恩公司 | 木-lna类似物 |
| AU3418800A (en) | 1999-03-24 | 2000-10-09 | Exiqon A/S | Improved synthesis of (2.2.1)bicyclo nucleosides |
| US6350868B1 (en) | 1999-04-26 | 2002-02-26 | University Of North Carolina At Chapel Hill | Antisense human fucosyltransferase sequences and methods of use thereof |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| ATE324888T1 (de) | 1999-06-14 | 2006-06-15 | Cancer Rec Tech Ltd | Krebstherapie |
| AU768904B2 (en) | 1999-06-21 | 2004-01-08 | Murdoch Childrens Research Institute, The | A method for the prophylaxis and/or treatment of medical disorders |
| US6168950B1 (en) | 1999-07-23 | 2001-01-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEKK1 expression |
| JP2003511016A (ja) | 1999-10-04 | 2003-03-25 | エクシコン エ／エス | オリゴヌクレオチドを補充する高親和性ｒｎアーゼｈの設計 |
| US6706505B1 (en) | 2000-03-08 | 2004-03-16 | Amgen Inc | Human E3α ubiquitin ligase family |
| ES2300366T3 (es) | 2000-09-02 | 2008-06-16 | Grunenthal Gmbh | Oligonucleotidos antisentido contra el vr1. |
| ATE325806T1 (de) | 2000-10-04 | 2006-06-15 | Santaris Pharma As | Verbesserte synthese von purin-blockierten nukleinsäure-analoga |
| US7105656B2 (en) | 2000-10-26 | 2006-09-12 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| WO2002094250A2 (en) | 2001-05-18 | 2002-11-28 | Cureon A/S | Therapeutic uses of lna-modified oligonucleotides in infectious diseases |
| AU2002304163C1 (en) | 2001-06-05 | 2009-01-08 | Oriental Yeast Co., Ltd. | Polypeptide unstabilizing protein in cells under aerobic conditions and DNA encoding the same |
| US7153954B2 (en) | 2001-07-12 | 2006-12-26 | Santaris Pharma A/S | Method for preparation of LNA phosphoramidites |
| DE60202681T2 (de) | 2001-07-12 | 2006-01-12 | Santaris Pharma A/S | Verfahren zur herstellung des lna phosphoramidite |
| WO2003085110A2 (en) * | 2002-04-05 | 2003-10-16 | Santaris Pharma A/S | Oligomeric compounds for the modulation hif-1alpha expression |
| ES2290448T3 (es) | 2002-05-08 | 2008-02-16 | Santaris Pharma A/S | Sistesis de derivados de acidos nucleicos bloqueados. |
| MXPA05004722A (es) * | 2002-11-01 | 2005-08-03 | Univ Pennsylvania | Composiciones y metodos para la inhibicion del factor inducible por hipoxia 1 alfa con acido ribonucleico corto de interferencia. |
| EP2752488B1 (en) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
| US7144999B2 (en) * | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
| AU2004209599A1 (en) | 2003-02-10 | 2004-08-19 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
| DE602004022020D1 (de) | 2003-02-10 | 2009-08-27 | Santaris Pharma As | Oligomere verbindungen zur modulation der expression von survivin |
| CA2587173C (en) * | 2004-11-09 | 2016-09-06 | Santaris Pharma A/S | Potent lna oligonucleotides for the inhibition of hif-1a expression |
-
2005
- 2005-11-09 CA CA2587173A patent/CA2587173C/en not_active Expired - Fee Related
- 2005-11-09 MX MX2007005558A patent/MX2007005558A/es unknown
- 2005-11-09 AT AT05800760T patent/ATE476441T1/de not_active IP Right Cessation
- 2005-11-09 BR BRPI0515726A patent/BRPI0515726A8/pt not_active Application Discontinuation
- 2005-11-09 EP EP05800760A patent/EP1833840B9/en not_active Expired - Lifetime
- 2005-11-09 US US11/271,686 patent/US7589190B2/en not_active Expired - Fee Related
- 2005-11-09 EA EA200701033A patent/EA014097B1/ru not_active IP Right Cessation
- 2005-11-09 WO PCT/DK2005/000721 patent/WO2006050734A2/en not_active Ceased
- 2005-11-09 DE DE602005022768T patent/DE602005022768D1/de not_active Expired - Lifetime
- 2005-11-09 DK DK05800760.0T patent/DK1833840T3/da active
- 2005-11-09 NZ NZ555644A patent/NZ555644A/en not_active IP Right Cessation
- 2005-11-09 KR KR1020077012303A patent/KR101176245B1/ko not_active Expired - Fee Related
- 2005-11-09 JP JP2007539463A patent/JP4825807B2/ja not_active Expired - Fee Related
- 2005-11-09 AU AU2005304112A patent/AU2005304112B2/en not_active Ceased
-
2007
- 2007-05-08 IL IL183054A patent/IL183054A0/en not_active IP Right Cessation
- 2007-06-08 NO NO20072933A patent/NO341878B1/no not_active IP Right Cessation
-
2009
- 2009-06-03 US US12/477,261 patent/US7939507B2/en not_active Expired - Fee Related
-
2011
- 2011-04-04 US US13/079,525 patent/US8410071B2/en not_active Expired - Fee Related
- 2011-08-15 JP JP2011177731A patent/JP2011229540A/ja not_active Withdrawn
-
2014
- 2014-02-21 JP JP2014031436A patent/JP2014098027A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008518608A5 (enExample) | ||
| JP6899509B2 (ja) | 呼吸器疾患関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含む呼吸器疾患予防または治療用組成物 | |
| JP7007304B2 (ja) | Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子 | |
| KR102208588B1 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| JP5981625B2 (ja) | Ｈｓｆ１関連疾患を処置するための有機組成物 | |
| JP2022515503A (ja) | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 | |
| JP2016513976A5 (enExample) | ||
| JP2022534702A (ja) | 核酸、薬物組成物及び複合体ならびに調製方法と使用 | |
| JP2022534069A (ja) | 核酸、薬物組成物及び複合体並びに調製方法と使用 | |
| WO2013105022A2 (en) | Organic compositions to treat beta-catenin-related diseases | |
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| KR101715228B1 (ko) | 뎅기 바이러스 특이적 siRNA, 그러한 siRNA 를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물 | |
| US9233119B2 (en) | Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells | |
| EP3268011A2 (en) | Inhibitors of dek protein and related methods | |
| JP5730508B2 (ja) | 炎症性腸疾患の治療又は予防剤 | |
| TW202603167A (zh) | 用於抑制ｆｘｉ表現之聚核酸分子、醫藥組合物及其用途 | |
| KR20260007508A (ko) | 진균 표적 안티센스 올리고뉴클레오타이드 및 이의 용도 | |
| AU2014280918B2 (en) | Organic compositions to treat HSF1-related diseases | |
| HK40016323A (en) | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease | |
| BR112016000163B1 (pt) | Estrutura de oligo rna de dupla hélice, nanopartículas, composição farmacêutica e formulação liofilizada | |
| AU2017201838A1 (en) | Organic compositions to treat Beta-ENac-related diseases | |
| NZ788062A (en) | Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection |